Key facts
- This page summarizes Lindsay Androski's Form 4 filing for Eloxx Pharmaceuticals, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 28 Jan 2025, 17:35.
Lindsay Androski - 24 Jan 2025 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc.
- Reporting relationship
- Director
- Issuer ticker
- ELOX on Nasdaq
- Reported as of
- 24 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Jan 2025, 17:35:27 UTC
- Prior SEC filing
- 17 Oct 2024
- Next SEC filing
- 06 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sumit Aggarwal, Attorney-in-Fact for Androski Lindsay
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Lindsay Androski filed Form 4 for Eloxx Pharmaceuticals, Inc. on 28 Jan 2025.
Change
- Previous filing in this sequence was filed on 17 Oct 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ELOX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +3,750
- Change %
- +31%
- Price
- $0.000000
- Shares after
- 15,750
- Date
- 24 Jan 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELOX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -3,750
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 3,750
- Date
- 24 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,750
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
Footnote F2
The RSUs vest as to 50% on the first anniversary of January 24, 2024 and, as to the remaining amount, in two equal annual installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each applicable vesting date.